HIV-1 逆转录酶进入通道的延伸——晶体学和增强的可溶性。
Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.
机构信息
Department of Chemistry, Yale University, New Haven, CT 06520-8107, USA.
出版信息
Bioorg Med Chem Lett. 2013 Sep 15;23(18):5209-12. doi: 10.1016/j.bmcl.2013.06.093. Epub 2013 Jul 8.
Abstract
Non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-RT) are reported that feature extension into the entrance channel near Glu138. Complexes of the parent anilinylpyrimidine 1 and the morpholinoethoxy analog 2j with HIV-RT have received crystallographic characterization confirming the designs. Measurement of aqueous solubilities of 2j, 2k, the parent triazene 2a, and other NNRTIs demonstrate profound benefits for addition of the morpholinyl substituent.
摘要
报道了一类新型的 HIV-1 逆转录酶（HIV-RT）非核苷抑制剂，其特征是在靠近 Glu138 的入口通道处延伸。母体苯胺基嘧啶 1 和吗啉乙氧基类似物 2j 与 HIV-RT 的复合物已通过晶体学表征得到证实。测量 2j、2k、母体三嗪 2a 和其他 NNRTIs 的水溶解度表明，引入吗啉基取代基具有显著的益处。
相似文献
1
Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.
Bioorg Med Chem Lett. 2013 Sep 15;23(18):5209-12. doi: 10.1016/j.bmcl.2013.06.093. Epub 2013 Jul 8.
2
Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
Eur J Med Chem. 2021 Dec 15;226:113868. doi: 10.1016/j.ejmech.2021.113868. Epub 2021 Sep 22.
3
Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase.
Bioorg Med Chem Lett. 2012 Feb 15;22(4):1565-8. doi: 10.1016/j.bmcl.2011.12.132. Epub 2012 Jan 5.
4
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
J Med Chem. 2004 Nov 18;47(24):5912-22. doi: 10.1021/jm040071z.
5
Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
Bioorg Med Chem Lett. 2010 Oct 15;20(20):6020-3. doi: 10.1016/j.bmcl.2010.08.068. Epub 2010 Aug 19.
6
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
J Med Chem. 2004 Nov 18;47(24):5923-36. doi: 10.1021/jm040072r.
7
Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase.
Bioorg Med Chem Lett. 2015 Nov 1;25(21):4824-4827. doi: 10.1016/j.bmcl.2015.06.074. Epub 2015 Jul 9.
8
Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Eur J Med Chem. 2013 Jul;65:134-43. doi: 10.1016/j.ejmech.2013.04.052. Epub 2013 May 3.
9
Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.
Eur J Med Chem. 2012 Dec;58:485-92. doi: 10.1016/j.ejmech.2012.10.036. Epub 2012 Oct 29.
10
Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group.
J Am Chem Soc. 2013 Nov 6;135(44):16705-13. doi: 10.1021/ja408917n. Epub 2013 Oct 24.
引用本文的文献
1
A Pharmacological Overview and Recent Patent of Triazine Scaffold in Drug Development: A Review.
Curr Org Synth. 2025;22(3):310-327. doi: 10.2174/0115701794272212240307092318.
2
Novel 2-(Diphenylmethylidene) Malonic Acid Derivatives as Anti-HIV Agents: Molecular Modeling, Synthesis and Biological Evaluation.
Iran J Pharm Res. 2021 Dec 14;21(1):e123827. doi: 10.5812/ijpr.123827. eCollection 2022 Dec.
3
Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase.
Front Mol Biosci. 2022 Feb 14;9:805187. doi: 10.3389/fmolb.2022.805187. eCollection 2022.
4
Design, antihuman immunodeficiency activity and molecular docking studies of synthesized 2-aryl and 2-pyrimidinyl pyrrolidines.
Mol Divers. 2021 Nov;25(4):2045-2052. doi: 10.1007/s11030-020-10095-1. Epub 2020 May 5.
5
Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Acta Pharm Sin B. 2020 Feb;10(2):344-357. doi: 10.1016/j.apsb.2019.09.007. Epub 2019 Oct 17.
6
Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2182-2188. doi: 10.1016/j.bmcl.2019.06.047. Epub 2019 Jun 26.
7
Unbinding Dynamics of Non-Nucleoside Inhibitors from HIV-1 Reverse Transcriptase.
J Phys Chem B. 2019 Feb 28;123(8):1741-1748. doi: 10.1021/acs.jpcb.8b10341. Epub 2019 Jan 3.
8
Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
Eur J Med Chem. 2018 Sep 5;157:1017-1030. doi: 10.1016/j.ejmech.2018.08.058. Epub 2018 Aug 22.
9
Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility.
J Enzyme Inhib Med Chem. 2018 Dec;33(1):9-16. doi: 10.1080/14756366.2017.1387542.
10
Structural biology in antiviral drug discovery.
Curr Opin Pharmacol. 2016 Oct;30:116-130. doi: 10.1016/j.coph.2016.08.014. Epub 2016 Sep 6.
本文引用的文献
1
Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design.
J Am Chem Soc. 2012 Dec 5;134(48):19501-3. doi: 10.1021/ja3092642. Epub 2012 Nov 19.
2
Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.
J Med Chem. 2012 Aug 23;55(16):7219-29. doi: 10.1021/jm3007678. Epub 2012 Aug 10.
3
Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Bioorg Med Chem Lett. 2012 Apr 1;22(7):2376-9. doi: 10.1016/j.bmcl.2012.02.055. Epub 2012 Feb 24.
4
Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase.
Bioorg Med Chem Lett. 2012 Feb 15;22(4):1565-8. doi: 10.1016/j.bmcl.2011.12.132. Epub 2012 Jan 5.
5
Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
J Med Chem. 2011 Dec 22;54(24):8582-91. doi: 10.1021/jm201134m. Epub 2011 Nov 29.
6
Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase.
J Am Chem Soc. 2011 Oct 5;133(39):15686-96. doi: 10.1021/ja2058583. Epub 2011 Sep 9.
7
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Lancet. 2011 Jul 16;378(9787):238-46. doi: 10.1016/S0140-6736(11)60936-7.
8
Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
Bioorg Med Chem Lett. 2010 Apr 15;20(8):2485-8. doi: 10.1016/j.bmcl.2010.03.006. Epub 2010 Mar 4.
9
Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.
Ann Pharmacother. 2010 Jan;44(1):157-65. doi: 10.1345/aph.1M359. Epub 2009 Dec 8.
10
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
Antiviral Res. 2010 Jan;85(1):75-90. doi: 10.1016/j.antiviral.2009.09.008. Epub 2009 Sep 23.
Zotero 插件